High numbers of granzyme B/CD8‐positive tumour‐infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent
- 8 October 2002
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 198 (4) , 468-475
- https://doi.org/10.1002/path.1236
Abstract
This study determined whether tumour‐infiltrating lymphocytes (TILs) in nasopharyngeal carcinomas (NPCs) include activated cytotoxic T lymphocytes (CTLs) and whether the numbers of activated CTLs in these biopsies are related to clinical outcome. Moreover, the study investigated whether the numbers of activated CTLs are associated with the expression of MHC class I proteins and the granzyme B antagonist PI‐9 in the tumour cells. Forty‐three Indonesian NPC patients (T1–3, N1–3, M0), who were treated with curative intent by radiotherapy only, were studied. Tumour‐infiltrating activated CTLs were detected using antibodies against granzyme B, CD8, and CD56. Expression of MHC class I proteins and PI‐9 was also determined by immunohistochemistry. Granzyme B‐positive TILs were detected in all NPC biopsies. The presence of a high percentage (>25%) of granzyme B‐positive TILs appeared to be a very strong predictor of a rapid fatal clinical outcome, independent of stage. Complete absence of MHC class I heavy chain expression in tumour cells was observed in 11 of 31 evaluable cases and low levels were observed in seven additional cases. No association between MHC class I expression and the numbers of granzyme B‐positive TILs was observed. Expression of the granzyme B antagonist PI‐9 in tumour cells was detected in three cases. It is concluded that the presence of many granzyme B‐positive TILs in a selected group of Indonesian NPC patients is a strong and stage‐independent marker for a rapid fatal clinical outcome. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 29 references indexed in Scilit:
- Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations?International Journal of Radiation Oncology*Biology*Physics, 2001
- Epstein–Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of ChinaInternational Journal of Cancer, 1998
- Why certain antibodies cross-react with HLA- A and HLA-G: Epitope mapping of two common MHC class I reagentsfn2fn2This work was supported by a grant from the National Institutes of Health (R01AI38577-01) and by a Reproductive Scientist Development Award, the Society for Gynecologic Investigation, and National Institutes of Health Grant K12HD00849 (to D.J.S.)Molecular Immunology, 1998
- Biology and treatment of nasopharyngeal cancerCurrent Opinion in Oncology, 1995
- Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral bloodClinical and Experimental Immunology, 1995
- Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologueEuropean Journal Of Cancer, 1994
- Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinomaInternational Journal of Cancer, 1991
- Viral latency and transformation: The strategy of Epstein-Barr virusCell, 1989
- Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the NasopharynxNature, 1970
- Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: Antibodies to EBV associated Membrane and Viral Capsid Antigens in Burkitt Lymphoma PatientsNature, 1970